Floatz Rating
D29/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
14Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03207867CT.gov A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| nir178 (this asset) | Novartis Pharmaceuticals | P2 | D · 29 |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Pembrolizumab | Sutro Biopharma, Inc. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BB |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Vasgene Therapeutics, Inc | P2/3 | BB |
| Docetaxel | NuCana plc | P3 | BB |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P3 | BB |
| Carboplatin | Neonc Technologies, Inc. | P3 | BB |
+42 more in the Urothelial Carcinoma cohort
Other indications for nir178
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P2 | D · 30 |
| Colorectal Cancer | — | P2 | D · 30 |
| Triple-Negative Breast Carcinoma | — | P2 | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideBeijing BiotechBB
- PembrolizumabSutro Biopharma, Inc.BB
- Cis-Diamminedichloroplatinum IiNagoya UniversityBB
- DurvalumabAlliance for Clinical Trials in OncologyBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncBB
Citation
Floatz Terminal. nir178 in Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nir178-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →